Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response

Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response

Abstract Body composition is an important predictor in cancer patients, with skeletal muscle loss and high adiposity associated with poorer prognosis. This study evaluated how body composition affects treatment efficacy in 48 women with metastatic breast cancer receiving trastuzumab deruxtecan. Usin...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shiran Yaacobi Peretz, Rivka Kessner, Yael Bar, Amir Sonnenblick, Shir Lerner, Ariella Deutsch-Lukatsky, Karteek Popuri, Mirza Faisal Beg, Shlomit Strulov Shachar
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-04-01
Series:	npj Breast Cancer
Online Access:	https://doi.org/10.1038/s41523-025-00754-7
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comprehensive management strategy of interstitial lung disease induced by trastuzumab deruxtecan
by: ZHANG Jian, HAN Qian, XU Fei, GAN Lu, CHEN Zhanhong, MA Li, WANG Hao, LIU Jieqiong, WU Xiaohong, CAI Li, ZHAO Bing, LÜ Zheng, LI Li, NI Sujie, HU Xichun
Published: (2024-12-01)

Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
by: Nelson S Moss, et al.
Published: (2022-09-01)

Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: a systemic review and meta-analysis
by: Ali Hussain, et al.
Published: (2025-04-01)

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer
by: Jonathan Henricks, et al.
Published: (2025-02-01)

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01)

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01)

Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis
by: Hiroaki Yamane, et al.
Published: (2024-12-01)

Exceptional response to trastuzumab deruxtecan in recurrent neuroendocrine cervical cancer: A case report
by: Lauren Tostrud, et al.
Published: (2025-08-01)

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01)

Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia
by: N. A. Avxentyev, et al.
Published: (2024-07-01)

The efficacy of trastuzumab deruxtecan in Chinese breast cancer patients: a real-world multicenter study
by: Miao He, et al.
Published: (2025-08-01)

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
by: Li-Chung Tsao, et al.
Published: (2025-04-01)

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review
by: I. V. Kolyadina
Published: (2023-10-01)

Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01)

Safety and efficacy of combined trastuzumab-deruxtecan and concurrent radiation therapy in breast cancer. The TENDANCE multicentric French study
by: K. Debbi, et al.
Published: (2025-04-01)

Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience
by: Neda Yaghoubi, et al.
Published: (2025-05-01)

TRACKING HER2 TRAFFICKING AND ORGANELLE CROSSTALK IN TRASTUZUMAB-DERUXTECAN–TREATED BREAST CANCER CELLS USING MULTIMODAL IMAGING
Published: (2025-08-01)

Successful Treatment of HER2 V659E Mutation‐Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report
by: Mariko Nishihara, et al.
Published: (2025-06-01)

Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis
by: George W. Jr. Sledge, et al.
Published: (2025-08-01)

Trastuzumab-deruxtecan shows interesting disease control in a multitreated patient with ERBB2 amplified parotid carcinoma, a case report
by: Camille Evrard, et al.
Published: (2025-05-01)

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study
by: E. Fountzilas, et al.
Published: (2025-03-01)

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
by: Jinmei Zhou, et al.
Published: (2025-05-01)

Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer
by: Qi Cai, et al.
Published: (2025-12-01)

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study
by: K. Nakanishi, et al.
Published: (2025-06-01)

Successful Treatment of Innumerable Untreated Brain Metastases With Trastuzumab Deruxtecan in Chemotherapy-Naïve HER2-Mutated Non-Small-Cell Lung Cancer
by: Sara Young, et al.
Published: (2025-01-01)

Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports
by: Yan Meng, et al.
Published: (2025-08-01)

Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study
by: Fangfang Duan, et al.
Published: (2025-07-01)

Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings
by: Koshiro Fukuda, et al.
Published: (2025-04-01)

Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
by: Die Sang, et al.
Published: (2025-02-01)

Excellent Response to Trastuzumab Deruxtecan of a Large Medullary Metastasis from Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Case Report
by: Aoi Kuroda, et al.
Published: (2025-03-01)

Excellent efficacy of trastuzumab deruxtecan in a patient with HER2-positive advanced breast cancer complicated by pulmonary lymphangitic carcinomatosis: a case report and literature review
by: Simin Luo, et al.
Published: (2025-04-01)

Patritumab deruxtecan induces immunogenic cell death
by: Sabrina Forveille, et al.
Published: (2025-12-01)

Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
by: Salvatore Siena, et al.
Published: (2025-01-01)

Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
by: Laura A. Huppert, et al.
Published: (2025-04-01)

CT‐Based Body Composition and Frailty as Predictors of Survival Among Older Adults With Gastrointestinal Malignancies
by: Smith Giri, et al.
Published: (2025-02-01)

Datopotamab deruxtecan induces hallmarks of immunogenic cell death
by: Sabrina Forveille, et al.
Published: (2025-08-01)

Trastuzumab and cardiotoxicity
by: Petra Sertić, et al.
Published: (2024-01-01)

Target Points in Trastuzumab Resistance
by: Sahar Shojaei, et al.
Published: (2012-01-01)

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
by: Vincenzo Nasca, et al.
Published: (2025-04-01)